Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

30 January 2026

17 Pages

Novel Cell Cycle Inhibitors Decrease Primary and Metastatic Breast Cancer Growth In Vivo

,
,
,
,
,
,
,
,
…
1
Division of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Sanat Nagar, Srinagar 190005, Jammu & Kashmir, India
2
Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology Zurich (ETH Zurich), 8093 Zurich, Switzerland
3
Division of Medicinal Chemistry, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, Jammu & Kashmir, India
*
Authors to whom correspondence should be addressed.
This article belongs to the Section Cancer Metastasis

Simple Summary

Breast cancer is a leading cancer worldwide, with metastasis causing high death rates. Currently, patients with overt metastatic disease are considered incurable. We used patient-derived circulating tumor cells (CTCs) to screen 250 small molecules, identifying five compounds with potential anti-cancer effects. These compounds, which inhibit cyclin-dependent kinase (CDK-2/9), effectively reduced tumor growth and metastasis in mouse breast cancer models. Transcriptome profiling of treated cancer cells revealed alterations in pathways associated with cell cycle regulation, providing mechanistic insights into the anti-cancer effects of the compounds. Altogether, these results contribute to providing new therapeutic tools that could be implemented for the treatment of breast cancer.

Abstract

Background: Breast cancer is one of the most frequently diagnosed cancers worldwide, with metastasis contributing to high mortality rates. Current treatments for metastatic disease are limited, emphasizing the urgent need for novel therapeutic approaches. Methods: We conducted a small-molecule drug screen utilizing patient-derived circulating tumor cells (CTCs) as a platform to identify potential anti-cancer agents. We used a dye combination and a high-content imaging microscope to evaluate cellular viability upon compound treatment. Among the 250 small molecules tested, potential hits were identified. The efficacy of these compounds was investigated using in vitro and in vivo studies in mouse breast cancer models. Bulk RNA sequencing of treated cancer cells was performed to identify differentially expressed genes, with Gene Ontology enrichment analyses conducted for their functional characterization. Results: Our screen of a 250 small-molecule library led to the identification of five hits, derivatives of meriolins known to display cyclin-dependent kinase (CDK-2/9) inhibitory activity. Subsequent in vitro and in vivo studies validated the efficacy of these compounds in inhibiting cell cycle, tumor growth, and consequently, metastatic colonization in mouse breast cancer models. Treatment with single agents (15 mg/kg) in breast cancer mouse models demonstrated good tolerability in vivo. Transcriptome profiling of treated cancer cells revealed alterations in pathways associated with cell cycle regulation, providing mechanistic insights into the anti-cancer effects of the compounds. Conclusions: By integrating drug screens, transcriptomic analysis, and in vivo validation, our study contributes to the identification of novel promising candidates for the treatment of breast cancer.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.